Razi Cov Pars

Last updated

Razi Cov Pars
Vaccine description
Target SARS-CoV-2
Vaccine type Protein subunit
Clinical data
Routes of
administration
Intramuscular, Intranasal

Razi Cov Pars is a COVID-19 vaccine candidate developed by the Iranian Razi Vaccine and Serum Research Institute. [1] [2] [3]

Contents

It's the second Iranian COVID-19 vaccine reaching human trials [1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine. [4] [5]

Medical uses

It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray). [3]

Pharmacology

Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein. [2]

Manufacturing

It's planned to produce one million doses of the vaccine each month as of September 2021. [4]

Clinical trials

Clinical trials of Razi Cov Pars
PhaseRegistration numberStartNumber of participantsAge of participantsRef
TotalVaccinePlacebo
I IRCT20201214049709N1 21 January 202113330 (5 µg/200µL)

30 (10 µg/200µL)

30 (20 µg/200µL)

30 (placebo)

13 (sentinel)

18-50 years [2]
II IRCT20201214049709N2 13 April 202150018-70 years [3]
III IRCT20201214049709N3 29 August 202141,12820,5640 (placebo)

20,564 (Sinopharm BIBP vaccine)

18+ years [5]

Related Research Articles

Razi Vaccine and Serum Research Institute

The Razi Vaccine and Serum Research Institute is an Iranian pharmaceutical company. It is located in the Hessarak district in Karaj, Iran. The Institute was built as a national center with the purpose of countering epidemics in domestic animals during Reza Shah era. Further departments were installed, including those dedicated to human medicines. In modern years, the Institute has focused primarily on nanomedicine and biotechnology.

Convidecia Vaccine against COVID-19

AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics. It conducted its Phase III trials in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.

ZF2001 Vaccine against COVID-19

ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.

CoVLP COVID-19 vaccine candidate produced in a plant

CoVLP is a COVID-19 vaccine candidate developed by Medicago and GlaxoSmithKline (GSK). It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.

Soberana 02 Vaccine against COVID-19

Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. The vaccine is known as Pasto Covac in Iran, where it has been developed in collaboration with the Pasteur Institute of Iran.

COVIran Barekat COVIran Barakat vaccine against COVID-19

COVIran Barekat is a COVID-19 vaccine developed in Iran by Shifa Pharmed Industrial Group, a subsidiary of the Barkat Pharmaceutical Group. It is an inactivated virus-based vaccine. Iranian authorities have authorized its emergency use. This makes it the first locally-developed COVID-19 vaccine to be approved for emergency use in the Middle East.

EpiVacCorona EpiVacCorona vaccine against COVID-19

EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants.

ZyCoV-D Vaccine candidate against COVID-19

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.

SCB-2019 Vaccine candidate against COVID-19

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.

Sanofi–GSK COVID-19 vaccine Vaccine candidate against COVID-19

The Sanofi–GSK COVID-19 vaccine code-named VAT00002 and VAT00008 is a COVID-19 vaccine candidate developed by Sanofi Pasteur and GSK.

Sinopharm WIBP COVID-19 vaccine Vaccine against COVID-19

The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases. The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.

MVC COVID-19 vaccine Vaccine against COVID-19

The MVC COVID-19 vaccine, designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine , is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies and the U.S. National Institute of Health.

Viral vector vaccine Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material coding for a desired antigen into the recipient's host cells. As of April 2021, six viral vector vaccines have been authorized for use in humans in at least one country: four COVID-19 vaccines and two Ebola vaccines.

Corbevax Vaccine candidate against COVID-19 and infertility

Corbevax or BioE COVID-19, is a COVID-19 vaccine candidate developed by Indian biopharmacutical firm Biological E. Limited (BioE), the Baylor College of Medicine in Houston, United States, and American company Dynavax Technologies (DVAX). It is a protein subunit vaccine.

FAKHRAVAC Vaccine against COVID-19

FAKHRAVAC is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It's the third Iranian COVID-19 vaccine reaching clinical trials. It's currently in phase III. It has received emergency use authorization in Iran on 9 September 2021.

COVAX-19 Vaccine candidate against COVID-19

COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian based biotech company Vaxine. It is under clinical trial in collaboration with the Iranian company CinnaGen.

GBP510 Vaccine candidate against COVID-19

GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.

COVID-19 vaccine clinical research

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. 24 vaccines are authorized for use by national governments, including six approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; while five are in Phase IV. 204 vaccines are undergoing clinical trials that have yet to be authorized. Nine clinical trials consider heterologous vaccination courses.

Noora (vaccine) Vaccine candidate against COVID-19

Noora is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in Iran.

Soberana Plus

Soberana Plus, technical name FINLAY-FR-1A, is a COVID-19 candidate vaccine produced by the Finlay Institute, a Cuban epidemiological research institute.

References

  1. 1 2 Mehdi, Syed Zafar (7 February 2021). "Iran unveils second homegrown COVID-19 vaccine". Anadolu Agency. Retrieved 22 April 2021.
  2. 1 2 3 "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.
  3. 1 2 3 "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.
  4. 1 2 "COVID-19 vaccine Razi Cov Pars starts third clinical trial phase". Tehran Times. 27 August 2021. Retrieved 30 August 2021.
  5. 1 2 "IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial". en.irct.ir. Retrieved 30 August 2021.